TG Therapeutics (TGTX) Tops Q3 EPS by 12c

TG Therapeutics (NASDAQ: TGTX) reported Q3 EPS of ($0.26), $0.12 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $2.03 million versus the consensus estimate of $1.46 million.

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.

You May Also Be Interested In

• Cellebrite DI Ltd. (CLBT) Tops Q2 EPS by 4c ; Offers Guidance
• Idaho Strategic Resources, Inc. (IDR) Misses Q2 EPS by 4c
• Applied Industrial Technologies (AIT) Tops Q4 EPS by 25c, Beats on Revenue; Offers FY27 EPS Guidance